



---

Open Access Journal by MDPI

---

Impact Factor 3.4

CiteScore 2.6

Indexed in PubMed

# Journal of Personalized Medicine



[mdpi.com/  
journal/  
jpm](https://mdpi.com/journal/jpm)



# Message from the Editor-in-Chief

*Journal of Personalized Medicine* is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

---

## Editor-in-Chief

Prof. Dr. David Alan Rizzieri

---

## Aims

*Journal of Personalized Medicine (JPM; ISSN 2075-4426)* is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, omics association analysis).

For a comprehensive perspective of primary research, commentaries, and reviews related to personalized medicine, also termed precision medicine, *JPM* aims to integrate expertise from the molecular and translational sciences, therapeutics and diagnostics, as well as discussions of regulatory, social, ethical and policy aspects. We provide a forum to bring together academic and clinical researchers, biotechnology, diagnostic and pharmaceutical companies, health professionals, regulatory and ethical experts, and government and regulatory authorities.

---

## Scope

Topics of interest with a view towards personalized medicine include (but are not limited to) the following:

- Omics-based studies of disease risk, disease prognosis, and response to therapy
- Biomarker identification and application
- Drug target discovery and integration with individualized therapy
- Pharmacogenomics – genetics and biochemistry of drug uptake, action, and metabolism
- Prediction-based drug safety
- Novel therapeutics: genetic-based, nanotechnology, targeting strategies
- Advancements in Technologies and Resources
  - Genetic testing, sequencing technologies, and molecular diagnostics
  - Expression analysis, metabolomics, proteomics
  - Microbiomes
  - Genome-wide association studies
  - Bioinformatics and health informatics
  - Biostatistics
- Personalization of omics-based non-drug related health interventions
- Regulation and bioethics in personalized medicine

---

## Author Benefits

### Open Access

Unlimited and free access for readers

### No Copyright Constraints

Retain copyright of your work and free use of your article

### Thorough Peer-Review

### No Space Constraints, No Extra Space or Color Charges

No restriction on the maximum length of the papers, number of figures or colors

### Coverage by Leading Indexing Services

Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases

### Rapid Publication

A first decision is provided to authors approximately 17.8 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the second half of 2023)

MDPI is a member of

CASPA



STM<sup>1</sup>



SPARC\*  
Europe



DOAJ



ORCID



**Editorial Office**

[jpm@mdpi.com](mailto:jpm@mdpi.com)

MDPI

St. Alban-Anlage 66

4052 Basel, Switzerland

Tel: +41 61 683 77 34

[mdpi.com](http://mdpi.com)

